Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia
暂无分享,去创建一个
A. Chatterjee | S. Litovsky | S. Pamboukian | C. Hoopes | J. Tallaj | I. Rajapreyar | A. Lenneman | C. Lenneman | J. Joly | A. Assad
[1] Paul G. Williams,et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.
[2] M. Gertz. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018 , 2018, Blood Cancer Journal.
[3] M. Bayliss,et al. Light Chain (AL) Amyloidosis: The Journey to Diagnosis , 2017, The Patient - Patient-Centered Outcomes Research.
[4] B. Barlogie,et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease , 2017, American journal of hematology.
[5] A. Dispenzieri,et al. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response , 2017, Heart.
[6] A. Dispenzieri,et al. Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases , 2017, European Respiratory Journal.
[7] M. Dhodapkar. MGUS to myeloma: a mysterious gammopathy of underexplored significance. , 2016, Blood.
[8] M. Dimopoulos,et al. Recent advances in the management of AL Amyloidosis , 2016, British journal of haematology.
[9] H. Mizuno,et al. Pulmonary arterial hypertension due to pulmonary vascular amyloid deposition in a patient with multiple myeloma. , 2015, International journal of clinical and experimental pathology.
[10] T. Mark,et al. Pulmonary Hypertension Complicating Multiple Myeloma , 2015, Pulmonary circulation.
[11] M. Lacy,et al. Severe Reversible Pulmonary Hypertension in Smoldering Multiple Myeloma: Two Cases and Review of the Literature , 2015, Pulmonary circulation.
[12] T. Kurihara,et al. Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. , 2014, Internal medicine.
[13] Wei Zhang,et al. Pulmonary hypertension in POEMS syndrome , 2013, Haematologica.
[14] T. Therneau,et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study , 2010, The Lancet.
[15] T. Therneau,et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.
[16] H. Bitterman,et al. Pulmonary Hypertension and Amyloidosis—an Uncommon Association: A Case Report and Review of the Literature , 2007, Journal of General Internal Medicine.
[17] R. Hoover,et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. , 2005, Blood.
[18] T. Therneau,et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.
[19] Terry M Therneau,et al. Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.
[20] D. Dingli,et al. Pulmonary hypertension in patients with amyloidosis. , 2001, Chest.
[21] D. Dahlin. Primary amyloidosis, with report of six cases. , 1949, The American journal of pathology.